Analysts Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) PT at $14.00

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has received an average recommendation of “Moderate Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, one has given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $14.00.

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 29th. Zacks Research raised shares of NeuroSense Therapeutics to a “hold” rating in a research report on Wednesday, October 15th. Noble Financial upgraded shares of NeuroSense Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. D. Boral Capital reissued a “buy” rating and set a $14.00 target price on shares of NeuroSense Therapeutics in a research note on Monday, December 22nd. Finally, Wall Street Zen upgraded shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NRSN. Two Sigma Investments LP purchased a new stake in shares of NeuroSense Therapeutics during the 3rd quarter worth about $26,000. Jane Street Group LLC bought a new position in NeuroSense Therapeutics during the second quarter valued at approximately $54,000. Finally, Squarepoint Ops LLC raised its position in NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after acquiring an additional 45,450 shares in the last quarter. 1.04% of the stock is owned by institutional investors and hedge funds.

NeuroSense Therapeutics Trading Up 2.3%

Shares of NRSN stock opened at $0.95 on Friday. NeuroSense Therapeutics has a 1-year low of $0.68 and a 1-year high of $2.60. The stock’s fifty day simple moving average is $0.95 and its 200-day simple moving average is $1.17.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.